|
Anoxia
|
0.400 |
Biomarker
|
phenotype |
LHGDN |
Endogenous hypoxia markers: case not proven!
|
18290322 |
2008 |
|
Anoxia
|
0.400 |
AlteredExpression
|
phenotype |
LHGDN |
In vitro, CA9 expression in cultured cells and culture medium was also induced by hypoxia (P<0.01).
|
18841153 |
2008 |
|
Anoxia
|
0.400 |
AlteredExpression
|
phenotype |
LHGDN |
Because fibrous remodeling of the subepithelium could limit delivery of nutrients and oxygen to the epithelium, we assessed expression of hypoxia-inducible factor-1alpha (HIF-1alpha) and carbonic anhydrase IX (CA IX) as markers of cellular hypoxia.
|
17674038 |
2007 |
|
Anoxia
|
0.400 |
Biomarker
|
phenotype |
CTD_human |
Role of carbonic anhydrase IX expression in prediction of the efficacy and outcome of primary epirubicin/tamoxifen therapy for breast cancer.
|
16954440 |
2006 |
|
Anoxia
|
0.400 |
AlteredExpression
|
phenotype |
LHGDN |
Taken together, our results suggest that besides the PI3K pathway, the MAPK cascade is involved in the regulation of CA9 gene expression under both hypoxia and high cell density.
|
15833446 |
2005 |
|
Anoxia
|
0.400 |
AlteredExpression
|
phenotype |
LHGDN |
In contrast, coexpression of HIF-1alpha and CAIX in the epithelium in phyllodes tumors points to epithelial hypoxia, most probably caused by relatively distant blood vessels.
|
16168127 |
2005 |
|
Anoxia
|
0.400 |
Biomarker
|
phenotype |
LHGDN |
Our findings suggest that hypoxia regulates both expression and activity of CA IX in order to enhance the extracellular acidification, which may have important implications for tumor progression.
|
15556624 |
2004 |
|
Anoxia
|
0.400 |
AlteredExpression
|
phenotype |
LHGDN |
The SP1/SP3 and hypoxia-response element in the CA9 promoter thus may represent a novel type of enhancer capable of mounting responses to a wider range of hypoxic conditions.
|
12615703 |
2003 |
|
Anoxia
|
0.400 |
AlteredExpression
|
phenotype |
LHGDN |
Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer.
|
12560438 |
2003 |
|
Anoxia
|
0.400 |
AlteredExpression
|
phenotype |
LHGDN |
The minimal cell density-dependent region within the CA9 promoter consists of the juxtaposed protected region 1 and hypoxia-response elements.
|
12154057 |
2002 |
|
Anoxia
|
0.400 |
Biomarker
|
phenotype |
LHGDN |
These observations suggested that CA9 might be a marker of clinically important hypoxia.
|
11705854 |
2001 |
|
Non-Small Cell Lung Carcinoma
|
0.380 |
AlteredExpression
|
disease |
BEFREE |
The objective of this study was to investigate PD-L1 expression and its correlation with hypoxic-inducible factor 1α (HIF1A), vascular endothelial growth factor A (VEGFA), glucose transporter 1 (GLUT1), and carbonic anhydrase 9 (CAIX) expression in NSCLC patients.
|
30797490 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
0.380 |
Biomarker
|
disease |
BEFREE |
CAIX might be a relevant prognostic marker in early stage NSCLC.
|
29845746 |
2018 |
|
Non-Small Cell Lung Carcinoma
|
0.380 |
Biomarker
|
disease |
BEFREE |
To assess the prognostic importance of carbonic anhydrase IX (CA IX), a hypoxic biomarker, after neoadjuvant treatment in Stage III non-small cell lung cancer (NSCLC) patients.
|
30029935 |
2018 |
|
Non-Small Cell Lung Carcinoma
|
0.380 |
Biomarker
|
disease |
CTD_human |
p53 mutants cooperate with HIF-1 in transcriptional regulation of extracellular matrix components to promote tumor progression.
|
30381462 |
2018 |
|
Non-Small Cell Lung Carcinoma
|
0.380 |
AlteredExpression
|
disease |
BEFREE |
We evaluated glucose transporter type 1 (GLUT1) and carbonic anhydrase IX (CAIX) expression, together with volume-based<sup>18</sup>F-fluorodeoxyglucose positron emission tomography (FDG-PET) parameters, in non-small cell lung cancer (NSCLC) patients, and examined the prognostic significance of those parameters according to its histologic subtype.
|
28212997 |
2017 |
|
Non-Small Cell Lung Carcinoma
|
0.380 |
Biomarker
|
disease |
BEFREE |
<b>Methods</b>: In this study, we evaluated for the first time the prognostic value of Plk1 mRNA and protein expression in combination with the <i>TP53</i> mutation status (next generation sequencing), induction of apoptotic cell death (immunohistochemistry for cleaved caspase 3) and hypoxia (immunohistochemistry for carbonic anhydrase IX (CA IX)) in 98 NSCLC adenocarcinoma patients.
|
28638459 |
2017 |
|
Non-Small Cell Lung Carcinoma
|
0.380 |
AlteredExpression
|
disease |
BEFREE |
In the present study we measured the mRNA expression of FL and AS CAIX isoforms in 101 NSCLC and in paired not affected tissues.
|
19022520 |
2009 |
|
Non-Small Cell Lung Carcinoma
|
0.380 |
AlteredExpression
|
disease |
BEFREE |
Quantitative analysis of carbonic anhydrase IX mRNA in human non-small cell lung cancer.
|
16513206 |
2006 |
|
Non-Small Cell Lung Carcinoma
|
0.380 |
AlteredExpression
|
disease |
BEFREE |
Standard immunohistochemical techniques were used to study CA IX expression in 175 resected NSCLC tumors.
|
12560438 |
2003 |
|
Noninfiltrating Intraductal Carcinoma
|
0.330 |
AlteredExpression
|
disease |
BEFREE |
CAIX overexpression was observed in 16.7% (3/18) of pure DCIS, in 37.9% (22/58) of DCIS-AIC and in 24.1% (14/58) of IC cases (n.s.).
|
31653758 |
2020 |
|
Noninfiltrating Intraductal Carcinoma
|
0.330 |
AlteredExpression
|
disease |
BEFREE |
In non-BRCA mutation-related cases the expression of the hypoxia markers in DCIS matched the expression in the invasive part in 46% or more of the cases.Although BRCA1 and BRCA2 germline mutation-related invasive breast cancers are different in many ways, the hypoxia-related proteins HIF-1α, CAIX and Glut-1 are expressed in both DCIS and invasive lesions of BRCA1 and BRCA2 mutation carriers.
|
23409121 |
2013 |
|
Noninfiltrating Intraductal Carcinoma
|
0.330 |
Biomarker
|
disease |
CTD_human |
GLUT1 and CAIX were expressed only in DCIS (56.8% and 25.0%) and IDC (44.1% and 30.5%), with higher expression in high grade DCIS than low/intermediate grade DCIS (79.2% vs. 30.0%, p = 0.001 and 37.5% vs. 10.0%, p = 0.036, respectively).
|
20526721 |
2010 |
|
Noninfiltrating Intraductal Carcinoma
|
0.330 |
AlteredExpression
|
disease |
BEFREE |
GLUT1 and CAIX were expressed only in DCIS (56.8% and 25.0%) and IDC (44.1% and 30.5%), with higher expression in high grade DCIS than low/intermediate grade DCIS (79.2% vs. 30.0%, p = 0.001 and 37.5% vs. 10.0%, p = 0.036, respectively).
|
20526721 |
2010 |
|
Ductal Carcinoma
|
0.320 |
AlteredExpression
|
disease |
BEFREE |
Two of these markers were cell surface carbonic anhydrase isozymes (CAIX and/or CAXII) and were validated for protein expression by immunohistochemistry of patient tissue samples on a breast cancer tissue microarray containing 47 normal breast tissue samples, 42 ductal carcinoma in situ, 43 invasive ductal carcinomas without metastasis, 46 invasive ductal carcinomas with metastasis, and 49 lymph node macrometastases of breast carcinoma.
|
22016510 |
2012 |